High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
Open Access
- 18 April 2006
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 94 (9), 1226-1230
- https://doi.org/10.1038/sj.bjc.6603097
Abstract
We investigated whether the occurrence of veno-occlusive disease of the liver (VOD) may be associated with individual variations in the pharmacokinetics of high-dose cyclophosphamide. Patients received single or multiple courses of cyclophosphamide (1000 or 1500 mg m−2 day−1), thiotepa (80 or 120 mg m−2 day−1) and carboplatin (265–400 mg m−2 day−1) (CTC) for 4 consecutive days. The area under the plasma concentration–time curves (AUCs) were calculated for cyclophosphamide and its activated metabolites 4-hydroxycyclophosphamide and phosphoramide mustard based on multiple blood samples. Possible relationships between the AUCs and the occurrence of VOD were studied. A total of 59 patients (115 courses) were included. Four patients experienced VOD after a second CTC course. The first-course AUC of 4-hydroxycyclophosphamide (P=0.003) but not of phosphoramide mustard (P=0.101) appeared to be predictive of the occurrence of VOD after multiple courses. High exposures to bioactivated cyclophosphamide may lead to increased organ toxicity.Keywords
This publication has 28 references indexed in Scilit:
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- Cyclophosphamide Metabolism in Children with Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast CancerNew England Journal of Medicine, 2003
- Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantationBlood, 2003
- Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatinAnnals Of Oncology, 2002
- Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancerBone Marrow Transplantation, 2001
- The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicityBone Marrow Transplantation, 2000
- Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustineAAPS PharmSci, 1999
- Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activationHepatology, 1996
- Cyclophosphamide ToxicityDrugs, 1991